Literature DB >> 30958517

Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis.

Laura Ambra Nicolini1,2, Paola Canepa1, Patrizia Caligiuri1, Malgorzata Mikulska1,2, Giovanni Novi3, Claudio Viscoli1,2, Antonio Uccelli3,4.   

Abstract

Entities:  

Year:  2019        PMID： 30958517      PMCID： PMC6583842          DOI： 10.1001/jamaneurol.2019.0522

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  5 in total

Review 1.  Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature.

Authors:  S Grisariu; I Vaxman; M Gatt; S Elias; B Avni; A Arad; O Pasvolsky; P Raanani; O Paltiel
Journal:  Hematol Oncol       Date:  2016-10-13       Impact factor: 5.271

2.  Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Authors:  Stephen L Hauser; Amit Bar-Or; Giancarlo Comi; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Xavier Montalban; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Jerry S Wolinsky; Douglas L Arnold; Gaelle Klingelschmitt; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Peter Chin; Nicole Mairon; Hideki Garren; Ludwig Kappos
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

3.  Severe hepatitis associated with an echovirus 18 infection in an immune-compromised adult.

Authors:  Martina I Lefterova; Claudia Rivetta; Tracy I George; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2012-11-21       Impact factor: 5.948

4.  A Case of Fulminant Hepatitis due to Echovirus 9 in a Patient on Maintenance Rituximab Therapy for Follicular Lymphoma.

Authors:  Ceri Morgan; S J Thomson; Joanne Legg; Santosh Narat
Journal:  Case Rep Hematol       Date:  2015-05-28

5.  Acute Liver Failure Due to Echovirus 9 Associated With Persistent B-Cell Depletion From Rituximab.

Authors:  Kristina L Bajema; Paul D Simonson; Alex L Greninger; Basak Çoruh; Paul S Pottinger; Renuka Bhattacharya; Iris W Liou; Florencia G Jalikis; Corinne L Fligner; Robert M Rakita
Journal:  Open Forum Infect Dis       Date:  2017-08-14       Impact factor: 3.835
  5 in total
  7 in total

1.  Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.

Authors:  Tereza Gabelić; Barbara Barun; Ivan Adamec; Magdalena Krbot Skorić; Mario Habek
Journal:  Hum Vaccin Immunother       Date:  2021-10-20       Impact factor: 4.526

Review 2.  [Ocrelizumab for treatment of multiple sclerosis].

Authors:  Jonas Graf; Philipp Albrecht; Norbert Goebels; Orhan Aktas; Hans-Peter Hartung
Journal:  Nervenarzt       Date:  2020-06-10       Impact factor: 1.214

Review 3.  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Authors:  Georges Jalkh; Rachelle Abi Nahed; Gabrielle Macaron; Mary Rensel
Journal:  Vaccines (Basel)       Date:  2020-12-26

Review 4.  Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2.

Authors:  Jonas Graf; Jan Mares; Michael Barnett; Orhan Aktas; Philipp Albrecht; Scott S Zamvil; Hans-Peter Hartung
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-12-16

Review 5.  The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.

Authors:  David Baker; Sandra Amor; Angray S Kang; Klaus Schmierer; Gavin Giovannoni
Journal:  Mult Scler Relat Disord       Date:  2020-05-12       Impact factor: 4.339

6.  Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS.

Authors:  Giovanni Novi; Federico Ivaldi; Elvira Sbragia; Malgorzata Mikulska; Giampaola Pesce; Matilde Inglese; Nicole Kerlero de Rosbo; Antonio Uccelli
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-02-25

Review 7.  The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.

Authors:  Marco Biolato; Assunta Bianco; Matteo Lucchini; Antonio Gasbarrini; Massimiliano Mirabella; Antonio Grieco
Journal:  CNS Drugs       Date:  2021-07-28       Impact factor: 5.749
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.